Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
13
×
Tags
biotech
13
×
crispr
13
×
life sciences
13
×
national blog main
boston blog main
boston top stories
national top stories
san francisco blog main
national
new york blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
editas medicine
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
indiana blog main
indiana top stories
ipo
novartis
gene editing
startups
abbvie
allergan
biogen
What
bio
roundup
crispr
gene
ceo
editas
life
medicine
medicines
moves
new
science
therapeutics
therapy
big
car
cas
companies
develop
diagnostics
editing
experimental
ipo
katrine
mammoth
million
millions
patients
remains
talk
week
years
abbvie
access
acquisitions
advanced
allergan
alliance
allogene
announced
Language
unset
unknown
Current search:
crispr
×
biotech
×
photo
×
" life sciences "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More